Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIS793 with/without spartalizumab plus chemotherapy in metastatic pancreatic cancer
NCT04390763Phase 2Terminated
- Sponsor
- Novartis
- Start
- Oct 2020
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
A Phase 2 trial of nisevokitug in pancreatic ductal adenocarcinoma (PDAC), sponsored by Novartis. Started Oct 2020; status: terminated.
02
Drugs
nisevokitug
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04390763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04390763.